Skip to content
10-Q

Quarterly Report

AGIOS PHARMACEUTICALS, INC. AGIO

0001439222-25-000036

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 25, 2025 57.92M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $78.96M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $76.25M
Current Liabilities Q1 2025 · Mar 31, 2025 $52.37M
Current Liabilities Q1 2025 · Dec 31, 2024 $81.16M
Total Liabilities Q1 2025 · Mar 31, 2025 $88.99M
Total Liabilities Q1 2025 · Dec 31, 2024 $122.24M
Current Assets Q1 2025 · Mar 31, 2025 $968.62M
Current Assets Q1 2025 · Dec 31, 2024 $965.6M
Total Assets Q1 2025 · Mar 31, 2025 $1.56B
Total Assets Q1 2025 · Dec 31, 2024 $1.66B
Shares Diluted Q1 2025 · Mar 31, 2024 56.38M sh
Capex Q1 2025 · Mar 31, 2024 $141K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$99.87M
Stockholders Equity Q1 2025 · Mar 31, 2024 $743.92M
Stockholders Equity Q1 2025 · Dec 31, 2023 $811.02M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.45
Eps Basic Q1 2025 · Mar 31, 2024 −$1.45
Sga Expense Q1 2025 · Mar 31, 2024 $31.01M
Rd Expense Q1 2025 · Mar 31, 2024 $68.62M
Net Income Q1 2025 · Mar 31, 2024 −$81.55M
Operating Income Q1 2025 · Mar 31, 2024 −$92.07M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $627K
Revenue Q1 2025 · Mar 31, 2024 $8.19M